{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-261704","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.379253+00:00","generated_at":"2026-06-09T14:02:53.439640+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"EMA grants PRIME designation for Annexon's ANX007 in geographic atrophy","bullets":["PRIME designation based on Phase 2 ARCHER trial showing preservation of visual function.","ANX007 is the first therapeutic candidate for GA to receive EMA PRIME designation.","Company engaging with U.S. and EU regulators to design global Phase 3 program.","Designation provides enhanced EMA support to expedite development and review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-261704","json":"https://secwatch.observer/filing/0001193125-23-261704.json","markdown":"https://secwatch.observer/filing/0001193125-23-261704.md","text":"https://secwatch.observer/filing/0001193125-23-261704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523261704/0001193125-23-261704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523261704/d482545d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T14:02:53.439640+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}